← back to search

Jan H. Cornel

Metropolitan University · NL
Area of research
Cardiology and Cardiovascular Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Cardiac Imaging and Diagnostics, Acute Myocardial Infarction Research, Cardiovascular Function and Risk Factors, and Lipoproteins and Cardiovascular Health.
h-index
67
citations
37,370
works
367
NIH funding
primary concept
Medicine
email

Recent publications

Colchicine for secondary prevention of vascular events: a meta-analysis of trials
European Heart Journal 2025cited by 41position: middledoi
Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis
Journal of the American College of Cardiology 2025cited by 20position: middledoi
Colchicine in Acute Myocardial Infarction
New England Journal of Medicine 2024cited by 245position: middledoi
Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials
EClinicalMedicine 2024cited by 53position: middledoi
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI
Journal of the American College of Cardiology 2024cited by 29position: middledoi
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
American Heart Journal 2024cited by 27position: middledoi
The effects of colchicine on lipoprotein(a)- and oxidized phospholipid-associated cardiovascular disease risk
European Journal of Preventive Cardiology 2024cited by 20position: middledoi
ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction
Journal of the American College of Cardiology 2024cited by 12position: middledoi
Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio
JAMA Cardiology 2022cited by 53position: middledoi
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials
European Heart Journal 2021cited by 249position: lastdoi
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease
The American Journal of Medicine 2021cited by 119position: middledoi
Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy
Atherosclerosis 2021cited by 62position: middledoi
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
Journal of the American College of Cardiology 2021cited by 57position: middledoi
Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis
PLoS ONE 2021cited by 29position: middledoi
Colchicine in Patients with Chronic Coronary Disease
New England Journal of Medicine 2020cited by 2,040position: middledoi
Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease
Circulation 2020cited by 142position: lastdoi
Ticagrelor in Patients with Stable Coronary Disease and Diabetes
New England Journal of Medicine 2019cited by 359position: middledoi
Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Journal of the American College of Cardiology 2018cited by 276position: lastdoi
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
New England Journal of Medicine 2017cited by 8,972position: middledoi
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
The Lancet 2017cited by 1,300position: middledoi
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
The Lancet 2017cited by 869position: middledoi
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
JAMA 2016cited by 1,137position: middledoi
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus
JAMA Cardiology 2016cited by 218position: middledoi
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Diabetes Care 2016cited by 188position: firstdoi
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes
Journal of the American College of Cardiology 2016cited by 108position: middledoi
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
The Lancet 2015cited by 147position: middledoi
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
New England Journal of Medicine 2012cited by 869position: middledoi
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial
European Heart Journal 2012cited by 106position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Aernoud T.L. Fiolet · Utrecht University6 papers (2020–2025)Arend Mosterd · The Centers6 papers (2020–2025)Willem A. Bax · Çevre, Şehircilik ve İklim Değişikliği Bakanlığı5 papers (2016–2025)Robert A. Harrington · Duke University4 papers (2016–2024)Dominique P.V. de Kleijn · Utrecht University4 papers (2020–2025)John W. Eikelboom · McMaster University4 papers (2021–2025)Kenneth W. Mahaffey · Stanford University3 papers (2016–2024)Peter Libby · Harvard University3 papers (2018–2024)Tjerk S.J. Opstal · Medisch Centrum Alkmaar3 papers (2020–2021)Renato D. Lópes · Alnylam Pharmaceuticals (United States)3 papers (2016–2024)Paul M. Ridker · Gentofte Hospital3 papers (2018–2024)José Carlos Nicolau · Beth Israel Deaconess Medical Center3 papers (2016–2024)Roxana Mehran · Icahn School of Medicine at Mount Sinai3 papers (2012–2024)Paul W. Armstrong · Canadian Armed Forces2 papers (2016–2016)Gilles Montalescot · ACTION2 papers (2012–2025)Wolfgang Köenig · Zimmer Biomet (United States)2 papers (2016–2018)Rury R. Holman · Indiana University Health2 papers (2016–2016)Binita Shah · Insmed (United States)2 papers (2021–2025)Stephen J. Nicholls · Australian Regenerative Medicine Institute2 papers (2016–2024)Harvey D. White · University of Auckland2 papers (2016–2024)